CXC Chemokines and HIV Pathogenesis

CXC 趋化因子和 HIV 发病机制

基本信息

项目摘要

DESCRIPTION (provided by applicant): We have recently shown that when monocyte-derived macrophages (MDM) are exposed to HIV-1, they produce large amounts of two C-X-C chemokines: Interleukin 8 (IL-8) and Growth-Regulated Oncogene alpha (GRO-alpha). This stimulation appears to be mediated by a pathway involving a tyrosine kinase, PKC-zeta, and perhaps NF-kappaB. IL-8 and GRO-alpha then, in turn, feed back and stimulate HIV-1 replication in both MDM and lymphocytes, likely by increasing viral entry. By blocking these chemokines or their receptors, CXCR1and/or CXCR2, we can inhibit HTV-1 replication. Companies have already developed agents that block the function of the above chemokines in order to treat inflammatory diseases, and we have demonstrated that a small molecule inhibitor of CXCR2 is able to inhibit HIV-1 replication. We now propose to examine the magnitude to which diverse clinical isolates of HIV stimulate the production of GRO-alpha and EL-8. The effect of IL-8 and GRO-alpha on the replication of a range of HIV isolates will also be assessed. These experiments will clarify how broadly applicable, and hence clinically important, these autocrine/paracrine loops involving chemokine, receptor, and HIV are. We will further test the hypothesis that HIV stimulates PKC-zeta and hence NF-kappaB, leading to increased transcription and production of IL-8 and GRO-alpha, which in turn stimulate HIV replication by augmenting viral entry. Thus, the proposed studies aim to further validate GRO-alpha and EL-8 and their receptors as targets for antiretroviral therapy. A mechanistic understanding of the interactions between HIV and these C-X-C chemokines could lead to the development of new approaches to the treatment of patients infected with HIV.
描述(由申请人提供):我们最近表明,当单核细胞衍生的巨噬细胞(MDM)暴露于HIV-1时,它们产生大量的两种C-X-C趋化因子:白细胞介素8(IL-8)和生长调节癌基因α(GRO-α)。这种刺激似乎是由涉及酪氨酸激酶、PKC-zeta和可能的NF-κ B的途径介导的。然后,IL-8和GRO-α反过来反馈并刺激HIV-1在MDM和淋巴细胞中的复制,可能是通过增加病毒进入。通过阻断这些趋化因子或其受体CXCR 1和/或CXCR 2,我们可以抑制HIV-1的复制。公司已经开发出阻断上述趋化因子功能的药物,以治疗炎症性疾病,我们已经证明CXCR 2的小分子抑制剂能够抑制HIV-1复制。我们现在建议检查不同的HIV临床分离株刺激GRO-α和EL-8产生的程度。还将评估IL-8和GRO-α对一系列HIV分离株复制的影响。这些实验将阐明这些涉及趋化因子、受体和HIV的自分泌/旁分泌循环的广泛适用性和临床重要性。我们将进一步检验HIV刺激PKC-zeta,从而刺激NF-κ B,导致IL-8和GRO-α的转录和产生增加,进而通过增强病毒进入刺激HIV复制的假设。因此,拟议的 研究旨在进一步验证GRO-α和EL-8及其受体作为抗逆转录病毒治疗的靶点。对HIV和这些C-X-C趋化因子之间相互作用的机制理解可能会导致开发治疗HIV感染患者的新方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Michael Markovitz其他文献

David Michael Markovitz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Michael Markovitz', 18)}}的其他基金

Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses
用于鼻内预防和治疗冠状病毒的分子工程凝集素
  • 批准号:
    10629566
  • 财政年份:
    2023
  • 资助金额:
    $ 35.58万
  • 项目类别:
DEK and TNF inhibitors in juvenile arthritis
DEK 和 TNF 抑制剂治疗幼年关节炎
  • 批准号:
    8311059
  • 财政年份:
    2009
  • 资助金额:
    $ 35.58万
  • 项目类别:
Replication of Human Endogenous Retroviruses in Modern Humans
人内源性逆转录病毒在现代人类中的复制
  • 批准号:
    8318290
  • 财政年份:
    2009
  • 资助金额:
    $ 35.58万
  • 项目类别:
Replication of Human Endogenous Retroviruses in Modern Humans
人内源性逆转录病毒在现代人类中的复制
  • 批准号:
    7762721
  • 财政年份:
    2009
  • 资助金额:
    $ 35.58万
  • 项目类别:
DEK and TNF inhibitors in juvenile arthritis
DEK 和 TNF 抑制剂治疗幼年关节炎
  • 批准号:
    8130630
  • 财政年份:
    2009
  • 资助金额:
    $ 35.58万
  • 项目类别:
DEK and TNF inhibitors in juvenile arthritis
DEK 和 TNF 抑制剂治疗幼年关节炎
  • 批准号:
    7835950
  • 财政年份:
    2009
  • 资助金额:
    $ 35.58万
  • 项目类别:
DEK and TNF inhibitors in juvenile arthritis
DEK 和 TNF 抑制剂治疗幼年关节炎
  • 批准号:
    7938774
  • 财政年份:
    2009
  • 资助金额:
    $ 35.58万
  • 项目类别:
Replication of Human Endogenous Retroviruses in Modern Humans
人内源性逆转录病毒在现代人类中的复制
  • 批准号:
    8119694
  • 财政年份:
    2009
  • 资助金额:
    $ 35.58万
  • 项目类别:
Replication of Human Endogenous Retroviruses in Modern Humans
人内源性逆转录病毒在现代人类中的复制
  • 批准号:
    8550159
  • 财政年份:
    2009
  • 资助金额:
    $ 35.58万
  • 项目类别:
CXC Chemokines and HIV Pathogenesis
CXC 趋化因子和 HIV 发病机制
  • 批准号:
    7160544
  • 财政年份:
    2005
  • 资助金额:
    $ 35.58万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 35.58万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 35.58万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 35.58万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.58万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 35.58万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 35.58万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 35.58万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 35.58万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 35.58万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 35.58万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了